Viral Hepatitis

The CDC developed new recommendations for testing algorithms and clinical management of health care personnel with the possibility of occupational exposure to hepatitis C, according guidance from Morbidity and Mortality Weekly Report.

In this exclusive video, Nancy S. Reau, MD, section chief of hepatology and associate director of organ transplantation at Rush University Medical Center, discusses some important aspects of treating liver diseases during the COVID-19 pandemic.

Data indicate that fewer medical students and fellows are joining the HIV workforce, perhaps under the impression that HIV is no longer the exciting and rewarding field it once was. We asked Peter Chin-Hong, MD, professor of medicine and director of the transplant infectious disease program at University of California, San Francisco (UCSF), what the “new HIV” is — the ID-related field that is attracting today’s young clinicians.

An analysis of peer-reviewed articles provided global prevalence estimates of hepatitis C virus in children, according to data from a modelling study.

Georgia’s hepatitis C virus elimination program made significant progress in helping diagnose patients and begin treatment, according to a study published in the Journal of Hepatology.

Patients with hepatocellular carcinoma had lower rates of sustained virologic response to treatment with direct-acting antiviral agents for hepatitis C than those without HCC, according to published results of a systematic review and meta-analysis.

According to study results published in JAMA, during a nearly 6-year period, only 30% of 13- to 21-year-olds with identified opioid, cocaine or amphetamine use who accessed U.S. federally qualified health centers in 19 states were tested for hepatitis C virus, suggesting a need to improve screening.

Patients who failed to achieve sustained virologic response after initial treatment for hepatitis C achieved high cure rates during retreatment after switching from an NS5A inhibitor direct-acting antiviral to a protease inhibitor.

Screening all patients with solid tumors for hepatitis B before they underwent chemotherapy was the most cost-effective strategy, compared with not screening or only screening high-risk patients, according to a published study.

Researchers discovered potential for a simplified monitoring schedule compared with standard monitoring among certain patients treated direct-acting antivirals for chronic hepatitis C, according to data published in Journal of Hepatology.